Searchable abstracts of presentations at key conferences in endocrinology

ea0015s4 | Society for Endocrinology European Medal Lecture | SFEBES2008

Unraveling the metabolic mysteries regulating body composition: new insights into old hormones

Ho Ken

Body composition is a major determinant of fitness and health. Many of the problems of aging are caused by detrimental changes in body composition. Hormones play a central role in the regulation of body composition. Our laboratory has been investigating the metabolic and molecular mechanisms of GH action and its interaction with sex steroids in the regulation body composition in adult human. The liver is an important site of physiological interaction as it is a sex steroid res...

ea0015s4biog | Society for Endocrinology European Medal Lecture | SFEBES2008

Society for Endocrinology Asia and Oceania Medal Lecture

Ho Ken K Y

Ken K Y Ho, University of New South Wales, Sydney, Australia AbstractKen Ho is a professor of Medicine at the University of New South Wales and is the Head, Pituitary Research Unit, Garvan Institute of Medical Research and Chairman, Department of Endocrinology, St. Vincent's Hospital, Sydney.He graduated in medicine at the University of Sydney in 1975, undertook research studies towards a Doctora...

ea0016p369 | Growth factors | ECE2008

New occurrence of diabetes mellitus in patients with adult onset GH deficiency (GHD) on GH therapy is dependent on the presence of metabolic syndrome at baseline: data from the Hypopituitary Control and Complication Study (HypoCCS)

Attanasio Andrea , Mo Daojun , Chanson Philippe , Ho Ken , Woodmansee Whitney , Kleinberg David , Erfurth Eva Marie

Patients with adult onset GHD (AO-GHD) manifest features of the metabolic syndrome (MetS) (abdominal obesity, dyslipidemia and insulin resistance), a condition associated with increased risk of diabetes mellitus (DM).We assessed metabolic status before and after 2 years of GH treatment and the occurrence of de novo DM in 712 patients with AO-GHD from HypoCCS drawn from the US (32.2%) and Europe (67.8%). Patients were divided into four BMI categori...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...